PMC:7558914 / 803-1526 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"39","span":{"begin":97,"end":105},"obj":"Species"},{"id":"40","span":{"begin":494,"end":502},"obj":"Species"},{"id":"45","span":{"begin":0,"end":12},"obj":"Chemical"},{"id":"46","span":{"begin":16,"end":35},"obj":"Chemical"},{"id":"47","span":{"begin":187,"end":205},"obj":"Chemical"},{"id":"48","span":{"begin":211,"end":223},"obj":"Chemical"},{"id":"49","span":{"begin":235,"end":253},"obj":"Chemical"},{"id":"50","span":{"begin":259,"end":278},"obj":"Chemical"},{"id":"51","span":{"begin":314,"end":332},"obj":"Chemical"},{"id":"52","span":{"begin":337,"end":356},"obj":"Chemical"},{"id":"53","span":{"begin":389,"end":407},"obj":"Chemical"},{"id":"54","span":{"begin":409,"end":421},"obj":"Chemical"},{"id":"55","span":{"begin":427,"end":446},"obj":"Chemical"},{"id":"56","span":{"begin":578,"end":591},"obj":"Chemical"},{"id":"57","span":{"begin":593,"end":611},"obj":"Chemical"},{"id":"58","span":{"begin":616,"end":626},"obj":"Chemical"},{"id":"67","span":{"begin":129,"end":139},"obj":"Disease"},{"id":"68","span":{"begin":515,"end":524},"obj":"Disease"}],"attributes":[{"id":"A39","pred":"tao:has_database_id","subj":"39","obj":"Tax:9606"},{"id":"A40","pred":"tao:has_database_id","subj":"40","obj":"Tax:9606"},{"id":"A45","pred":"tao:has_database_id","subj":"45","obj":"MESH:D017963"},{"id":"A46","pred":"tao:has_database_id","subj":"46","obj":"MESH:C558899"},{"id":"A47","pred":"tao:has_database_id","subj":"47","obj":"MESH:D006886"},{"id":"A48","pred":"tao:has_database_id","subj":"48","obj":"MESH:D017963"},{"id":"A49","pred":"tao:has_database_id","subj":"49","obj":"MESH:D006886"},{"id":"A50","pred":"tao:has_database_id","subj":"50","obj":"MESH:C558899"},{"id":"A51","pred":"tao:has_database_id","subj":"51","obj":"MESH:D006886"},{"id":"A52","pred":"tao:has_database_id","subj":"52","obj":"MESH:C558899"},{"id":"A53","pred":"tao:has_database_id","subj":"53","obj":"MESH:D006886"},{"id":"A54","pred":"tao:has_database_id","subj":"54","obj":"MESH:D017963"},{"id":"A55","pred":"tao:has_database_id","subj":"55","obj":"MESH:C558899"},{"id":"A56","pred":"tao:has_database_id","subj":"56","obj":"MESH:D003907"},{"id":"A57","pred":"tao:has_database_id","subj":"57","obj":"MESH:D008775"},{"id":"A58","pred":"tao:has_database_id","subj":"58","obj":"MESH:D011241"},{"id":"A67","pred":"tao:has_database_id","subj":"67","obj":"MESH:D011014"},{"id":"A68","pred":"tao:has_database_id","subj":"68","obj":"MESH:D011014"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"azithromycin or lopinavir/ritonavir was found in 40% of protocols. The recommended treatment for patients with mild and moderate pneumonias was different antiviral combinations including hydroxychloroquine plus azithromycin (93.3%) or hydroxychloroquine plus lopinavir/ritonavir (79.9%). Different combinations of hydroxychloroquine and lopinavir/ritonavir (46.7%) and triple therapy with hydroxychloroquine, azithromycin, and lopinavir/ritonavir (40%) were the most recommended treatments for patients with severe pneumonia. There were five corticosteroid regimens, which used dexamethasone, methylprednisolone, or prednisone, with different doses and treatment durations. Anakinra was included in seven protocols with six"}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T2","span":{"begin":129,"end":139},"obj":"Phenotype"},{"id":"T3","span":{"begin":515,"end":524},"obj":"Phenotype"}],"attributes":[{"id":"A2","pred":"hp_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/HP_0002090"},{"id":"A3","pred":"hp_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/HP_0002090"}],"text":"azithromycin or lopinavir/ritonavir was found in 40% of protocols. The recommended treatment for patients with mild and moderate pneumonias was different antiviral combinations including hydroxychloroquine plus azithromycin (93.3%) or hydroxychloroquine plus lopinavir/ritonavir (79.9%). Different combinations of hydroxychloroquine and lopinavir/ritonavir (46.7%) and triple therapy with hydroxychloroquine, azithromycin, and lopinavir/ritonavir (40%) were the most recommended treatments for patients with severe pneumonia. There were five corticosteroid regimens, which used dexamethasone, methylprednisolone, or prednisone, with different doses and treatment durations. Anakinra was included in seven protocols with six"}

{"project":"LitCovid-sentences","denotations":[{"id":"T9","span":{"begin":67,"end":287},"obj":"Sentence"},{"id":"T10","span":{"begin":288,"end":525},"obj":"Sentence"},{"id":"T11","span":{"begin":526,"end":673},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"azithromycin or lopinavir/ritonavir was found in 40% of protocols. The recommended treatment for patients with mild and moderate pneumonias was different antiviral combinations including hydroxychloroquine plus azithromycin (93.3%) or hydroxychloroquine plus lopinavir/ritonavir (79.9%). Different combinations of hydroxychloroquine and lopinavir/ritonavir (46.7%) and triple therapy with hydroxychloroquine, azithromycin, and lopinavir/ritonavir (40%) were the most recommended treatments for patients with severe pneumonia. There were five corticosteroid regimens, which used dexamethasone, methylprednisolone, or prednisone, with different doses and treatment durations. Anakinra was included in seven protocols with six"}